Service of Infectious Diseases and Service of Laboratory Medicine, Geneva University Hospitals and Geneva University, Geneva, Switzerland.
Division of Pneumology, Geneva University Hospitals, Geneva, Switzerland.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02088-17. Print 2018 Apr.
is a ubiquitous opportunistic pathogen. This fungus can acquire resistance to azole antifungals due to mutations in the azole target (). Recently, mutations typical for environmental azole resistance acquisition (for example, TR/L98H) have been reported. These mutations can also be found in isolates recovered from patients. Environmental azole resistance acquisition has been reported on several continents. Here we describe, for the first time, the occurrence of azole-resistant isolates of environmental origin in Switzerland with mutations, and we show that these isolates can also be recovered from a few patients. While the TR/L98H mutation was dominant, a single azole-resistant isolate exhibited a mutation (G54R) that was reported only for clinical isolates. In conclusion, our study demonstrates that azole resistance with an environmental signature is present in environments and patients of Swiss origin and that mutations believed to be unique to clinical settings are now also observed in the environment.
是一种普遍存在的机会性病原体。由于唑类药物靶标（）的突变，这种真菌可以获得对唑类抗真菌药物的耐药性。最近，已经报道了典型的环境唑类耐药获得（例如 TR/L98H）突变。这些突变也可以在从患者中回收的分离物中找到。环境唑类耐药性已在各大洲得到报道。在这里，我们首次描述了瑞士环境来源的唑类耐药 分离株存在 突变，并且我们表明这些分离株也可以从少数患者中回收。虽然 TR/L98H 突变占主导地位，但单个唑类耐药分离株表现出仅在临床分离株中报道的 突变（G54R）。总之，我们的研究表明，具有环境特征的唑类耐药性存在于瑞士来源的环境和患者中，并且现在在环境中也观察到了被认为仅存在于临床环境中的突变。
